{"ticker": {"uuid": "d81ef978-4e15-4f4e-93be-4a1e52989256", "symbol": "IMRN", "name": "Immuron Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 15, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 9, "label": "Earnings"}, {"count": 3, "label": "Market update"}, {"count": 2, "label": "Balance sheet"}, {"count": 1, "label": "Deals and strategy"}], "sources": [{"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 2}, {"label": "Kalkine", "count": 2}, {"label": "Kalkine Media", "count": 2}, {"label": "MT Newswires", "count": 1}, {"label": "Stocktwits", "count": 1}, {"label": "InvestorsHub", "count": 1}, {"label": "seekingalpha.com", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "55/100"}, {"text": "5.01 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "30/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "81/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Earnings"}, {"text": "100% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "15"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "13/100"}, {"text": "+2.7% over one week, +5.5% over four weeks, trend active, and below fair value.", "tone": "positive", "label": "Trend context", "value": "Trend active"}, {"text": "Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 9, "event": "earnings", "label": "Earnings", "weight": 5.48}, {"count": 3, "event": "general", "label": "Market update", "weight": 1.88}, {"count": 2, "event": "liquidity", "label": "Balance sheet", "weight": 1.2}, {"count": 1, "event": "deals", "label": "Deals and strategy", "weight": 0.6}], "pipeline": {"status": "partial", "providers_attempted": 4, "providers_with_results": 3, "raw_articles": 33, "unique_stories": 19, "duplicates_removed": 14, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 6, "direct_evidence": 15, "archive_articles": 3, "durable_story_count": 11, "durable_evidence_used": true, "durable_collected_at": "2026-09-04T01:47:20.672977+00:00"}, "confidence": 81, "primary_event": "earnings", "primary_label": "Earnings", "negative_events": 1, "positive_events": 5}, "updated_at": "2026-09-04T22:52:32.562457+00:00", "total_unique": 15, "total_fetched": 15, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 30, "event_label": "Earnings", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "positive", "latest_week": "2026-08-28", "trend_label": "Trend active", "latest_close": 1.15, "trend_signal": "1", "one_week_move": 2.7, "reaction_tone": "positive", "fair_value_gap": -35.3, "four_week_move": 5.5, "reaction_label": "Price confirming higher", "fair_value_tone": "positive", "market_dynamics": -0.025703, "market_sentence": "+2.7% over one week, +5.5% over four weeks, trend active, and below fair value.", "fair_value_label": "Below fair value", "twelve_week_move": -8.0, "relative_strength": -16.005996, "has_market_context": true, "expectation_direction": "negative", "expectation_probability": 43.4228, "market_dynamics_buy_signal": false}, "total_relevant": 15, "pipeline_health": {"status": "partial", "providers_attempted": 4, "providers_with_results": 3, "raw_articles": 33, "unique_stories": 19, "duplicates_removed": 14, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 6, "direct_evidence": 15, "archive_articles": 3, "durable_story_count": 15, "durable_evidence_used": true, "durable_collected_at": "2026-09-04T22:52:32.562457+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 55, "total": 15, "neutral": 9, "negative": 1, "positive": 5, "raw_score": 66, "confidence": 30, "dispersion": 13, "story_count": 15, "window_days": 30, "direct_share": 100, "source_count": 5, "score_version": "evidence-v10", "evidence_count": 6, "evidence_status": "provisional", "information_mass": 0.443, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-04T17:51:27+00:00", "direct_story_count": 15, "effective_articles": 5.01, "sector_story_count": 0, "direct_source_count": 5, "industry_story_count": 0, "source_concentration": 0.2133, "directional_story_count": 6}, "articles": [{"url": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "tier": "direct", "title": "Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "source_name": "MT Newswires", "published_at": "2026-09-04T17:51:27+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 98.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.069227, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 17:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/m/95d45f33-462e-3422-a666-8777fe2f0b31/imrn-stock-skyrockets-60%25%2C.html", "tier": "direct", "title": "IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years \u2013 What\u2019s Driving The Super Rally Today?", "topics": [], "summary": "", "age_days": 0.3, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/95d45f33-462e-3422-a666-8777fe2f0b31/imrn-stock-skyrockets-60%25%2C.html", "source_name": "Stocktwits", "published_at": "2026-09-04T14:50:54+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 89.1, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 14.2, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.063029, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 47, "published_display": "04 Sep 2026 14:50", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.2"}, {"url": "https://finance.yahoo.com/m/af240dd6-e316-3ccc-a55c-b572b83fbbd5/immuron-plans-u.s.-proibs.html", "tier": "direct", "title": "Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement", "topics": [], "summary": "", "age_days": 0.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/af240dd6-e316-3ccc-a55c-b572b83fbbd5/immuron-plans-u.s.-proibs.html", "source_name": "InvestorsHub", "published_at": "2026-09-04T13:53:25+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 87.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.044832, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 13:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/immuron-launch-proibs-united-states-100000457.html", "tier": "direct", "title": "Immuron to launch PROIBS\u00ae in the United States", "topics": [], "summary": "", "age_days": 0.5, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-launch-proibs-united-states-100000457.html", "source_name": "GlobeNewswire", "published_at": "2026-09-04T10:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 83.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.048034, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 10:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYUt0Ri16b2dUaXNIUkVjUHdBeHJrTUdMVHhoUldpMkZFbjlZQUdNQ0lXaU1FV3MxZUcyYjdxR2ZSQ0k2OEMyd2ZUNDhMRHlzWTJIYURSa19OLXRLNTRPMGd2THQ1cFd3YkRoMVR3czNNaXd2YVZtbTlhdzZsbnowcWtHdHJIQUZUaXlyLUtYeFZKRzBueGdsdVhNNTYzMElqR2JIWFBMVldWdUE?oc=5", "tier": "direct", "title": "Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss", "topics": [], "summary": "", "age_days": 7.4, "is_stale": false, "sentiment": "negative", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYUt0Ri16b2dUaXNIUkVjUHdBeHJrTUdMVHhoUldpMkZFbjlZQUdNQ0lXaU1FV3MxZUcyYjdxR2ZSQ0k2OEMyd2ZUNDhMRHlzWTJIYURSa19OLXRLNTRPMGd2THQ1cFd3YkRoMVR3czNNaXd2YVZtbTlhdzZsbnowcWtHdHJIQUZUaXlyLUtYeFZKRzBueGdsdVhNNTYzMElqR2JIWFBMVldWdUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T12:45:37+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 48.0, "sentiment_pct": 42, "evidence_basis": "headline_only", "evidence_share": 14.9, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.066069, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 44, "published_display": "28 Aug 2026 12:45", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.9"}, {"url": "https://seekingalpha.com/news/4637804-immuron-reports-fy-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "tier": "direct", "title": "Immuron reports FY results", "topics": ["Earnings", "Earnings News", "Ratings"], "summary": "* Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. * Net loss of A$3.8M, improvement of A$1.4M. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking Alpha\u2019s Quant Rating on Immuron [https://seekingalpha.com/symbol/IMRN/ratings/quant-ratings] * Historical earnings data for ", "age_days": 7.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4637804-immuron-reports-fy-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-28T10:12:40+00:00", "tone_signals": ["Operating growth"], "company_focus": 1.0, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.043278, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQjNqX2xpbmdDTGhuUUdvbFNTT2YwUkQxczBEaThnblJvbXNQYlFrempwRWpNT2U1amhmamhTaUZuNHdOLWdTOFNsSms4R0QzUldZaVJFckIxa1dNc010U015dDMtS3Bua1JqVXJJMXMwelJXMDVhQTlJYU1yeV85VXRvZVZrSHZUSElCTjBZWG9uS0ZlOHBCUENNVG00Q1VWUEttbnVORDBPbkh6NklsdFdZbWl5ajFRb09UMUhR?oc=5", "tier": "direct", "title": "Immuron Limited Reports Record FY26 Sales, Improved Profit and Key Pipeline Milestones", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQjNqX2xpbmdDTGhuUUdvbFNTT2YwUkQxczBEaThnblJvbXNQYlFrempwRWpNT2U1amhmamhTaUZuNHdOLWdTOFNsSms4R0QzUldZaVJFckIxa1dNc010U015dDMtS3Bua1JqVXJJMXMwelJXMDVhQTlJYU1yeV85VXRvZVZrSHZUSElCTjBZWG9uS0ZlOHBCUENNVG00Q1VWUEttbnVORDBPbkh6NklsdFdZbWl5ajFRb09UMUhR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-08-28T10:11:00+00:00", "tone_signals": ["Operating growth"], "company_focus": 1.0, "freshness_pct": 35.2, "sentiment_pct": 71, "evidence_basis": "headline_only", "evidence_share": 15.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.06968, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 55, "published_display": "28 Aug 2026 10:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "15.7"}, {"url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWlp3N1M4NjFrUHBzTnVyRWFackk3a25QZjJBUnZ3cjh0NE91S2syZ1FPVzYtbFNMWTlZTlBWS3djSE84dGlubVlqYzFpdENJQW9xd28ycjNRMmhQejUzLWFaQkJRNHdKNVFOSHV2dFowRXhQcHVlRGl6eXdHeUpEOXJ2NzBMdExDRzkxWDZTcjk?oc=5", "tier": "direct", "title": "Immuron's cash rose A$6.2M to A$9M; its C. diff drug is ready for Phase 2", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "sentiment": "neutral", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWlp3N1M4NjFrUHBzTnVyRWFackk3a25QZjJBUnZ3cjh0NE91S2syZ1FPVzYtbFNMWTlZTlBWS3djSE84dGlubVlqYzFpdENJQW9xd28ycjNRMmhQejUzLWFaQkJRNHdKNVFOSHV2dFowRXhQcHVlRGl6eXdHeUpEOXJ2NzBMdExDRzkxWDZTcjk?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T10:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 47.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.044859, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/immuron-reports-fy26-preliminary-results-100000596.html", "tier": "direct", "title": "Immuron Reports FY26 Preliminary Results", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-reports-fy26-preliminary-results-100000596.html", "source_name": "GlobeNewswire", "published_at": "2026-08-28T10:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.0328, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://kalkine.com.au/news/announcements/immuron-limited-reports-59-revenue-rise-and-reduced-full-year-loss-in-appendix-4e", "tier": "direct", "title": "Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan\u00ae sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.", "age_days": 7.6, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkine.com.au/news/announcements/immuron-limited-reports-59-revenue-rise-and-reduced-full-year-loss-in-appendix-4e", "source_name": "Kalkine", "published_at": "2026-08-28T09:15:00", "tone_signals": ["Loss narrowed", "Operating growth"], "company_focus": 1.0, "freshness_pct": 35.0, "sentiment_pct": 81, "evidence_basis": "archived_article", "evidence_share": 28.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.127612, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 67, "published_display": "28 Aug 2026 09:15", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "28.8"}, {"url": "https://kalkinemedia.com/au/news/announcements/immuron-reports-6-rise-in-fy26-global-sales-to-77-million-with-improved-net-loss", "tier": "direct", "title": "Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.", "age_days": 7.6, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/au/news/announcements/immuron-reports-6-rise-in-fy26-global-sales-to-77-million-with-improved-net-loss", "source_name": "Kalkine Media", "published_at": "2026-08-28T09:15:00", "tone_signals": ["Operating growth", "Improving financial comparison", "Fda Approval"], "company_focus": 1.0, "freshness_pct": 35.0, "sentiment_pct": 65, "evidence_basis": "archived_article", "evidence_share": 21.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.0966, "influence_label": "Medium", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 52, "published_display": "28 Aug 2026 09:15", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "21.8"}, {"url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-b9182ccdda73.html", "tier": "direct", "title": "Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and ProIBS, while seeking partners to fund the development and commercialization of its clinical assets IMM-124E and IMM-529. This shift aims to reduce R&D expenditure and cash burn, leveraging upfront fees, milestones, and royalties from licensing agreements.", "age_days": 16.5, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-b9182ccdda73.html", "source_name": "Stock Titan", "published_at": "2026-08-19T10:11:00", "tone_signals": ["Cash generation improved", "Strategic partnership"], "company_focus": 1.0, "freshness_pct": 10.1, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 4.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.020181, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 37, "published_display": "19 Aug 2026 10:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.6"}, {"url": "https://kalkine.com.au/news/announcements/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference", "tier": "direct", "title": "Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan\u00ae for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS\u00ae for IBS symptoms.", "age_days": 17.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkine.com.au/news/announcements/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference", "source_name": "Kalkine", "published_at": "2026-08-18T23:40:25", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 9.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.009136, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Aug 2026 23:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-2bd486add72e.html", "tier": "direct", "title": "Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelan\u00ae for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, and the distribution of ProIBS\u00ae for IBS symptoms. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.", "age_days": 22.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-2bd486add72e.html", "source_name": "Stock Titan", "published_at": "2026-08-13T09:42:33", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.004214, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 09:42", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://kalkinemedia.com/au/news/announcements/immuron-ceo-steven-lydeamore-to-deliver-virtual-presentation-at-emerging-growth-conference-on-august-19-2026", "tier": "direct", "title": "Immuron CEO Steven Lydeamore to Deliver Virtual Presentation at Emerging Growth Conference on August 19, 2026", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Eastern Time. The company, an Australian biopharmaceutical firm, specializes in orally delivered targeted polyclonal antibodies for infectious diseases, with its flagship product Travelan AE targeting travelers' diarrhea. Immuron is also developing IMM-529 for Clostridioides difficile infection.", "age_days": 22.6, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/au/news/announcements/immuron-ceo-steven-lydeamore-to-deliver-virtual-presentation-at-emerging-growth-conference-on-august-19-2026", "source_name": "Kalkine Media", "published_at": "2026-08-13T09:15:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.004203, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 09:15", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "tier": "direct", "title": "Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "bb303f8aba626235d3707168c8bb22e206319d4f8312b43debb797e3805314c9", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "source_name": "MT Newswires", "published_at": "2026-09-04T17:51:27+00:00", "source_names": ["MT Newswires"], "target_scope": "Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 98.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.069227, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.72, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 17:51", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/m/95d45f33-462e-3422-a666-8777fe2f0b31/imrn-stock-skyrockets-60%25%2C.html", "tier": "direct", "title": "IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years \u2013 What\u2019s Driving The Super Rally Today?", "topics": [], "summary": "", "age_days": 0.3, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "fe774bd0ed13849c7b377f1dd90518360e21ccf94c5e63c013447979e3f2f3db", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/95d45f33-462e-3422-a666-8777fe2f0b31/imrn-stock-skyrockets-60%25%2C.html", "source_name": "Stocktwits", "published_at": "2026-09-04T14:50:54+00:00", "source_names": ["Stocktwits"], "target_scope": "IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years \u2013 What\u2019s Driving The Super Rally Today?", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 89.1, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 14.2, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.063029, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.72, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.461, "provider_symbols": ["IMRN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 47, "published_display": "04 Sep 2026 14:50", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.2", "target_provider_symbol": "IMRN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/m/af240dd6-e316-3ccc-a55c-b572b83fbbd5/immuron-plans-u.s.-proibs.html", "tier": "direct", "title": "Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement", "topics": [], "summary": "", "age_days": 0.4, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "fa8974eb9a1e33e3d7ca0f9ae3503c3d0824891436d3b1acb260633df28b2a82", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/af240dd6-e316-3ccc-a55c-b572b83fbbd5/immuron-plans-u.s.-proibs.html", "source_name": "InvestorsHub", "published_at": "2026-09-04T13:53:25+00:00", "source_names": ["InvestorsHub"], "target_scope": "Immuron Plans U.S.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 87.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.044832, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.72, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["IMRN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 13:53", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/immuron-launch-proibs-united-states-100000457.html", "tier": "direct", "title": "Immuron to launch PROIBS\u00ae in the United States", "topics": [], "summary": "", "age_days": 0.5, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "77427ca4cce6c27298e953aa7d204ed9535724d5c78bb6026882b9e66632e40f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-launch-proibs-united-states-100000457.html", "source_name": "GlobeNewswire", "published_at": "2026-09-04T10:00:00+00:00", "source_names": ["GlobeNewswire"], "target_scope": "Immuron to launch PROIBS\u00ae in the United States", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 83.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.048034, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.72, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["IMRN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 10:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYUt0Ri16b2dUaXNIUkVjUHdBeHJrTUdMVHhoUldpMkZFbjlZQUdNQ0lXaU1FV3MxZUcyYjdxR2ZSQ0k2OEMyd2ZUNDhMRHlzWTJIYURSa19OLXRLNTRPMGd2THQ1cFd3YkRoMVR3czNNaXd2YVZtbTlhdzZsbnowcWtHdHJIQUZUaXlyLUtYeFZKRzBueGdsdVhNNTYzMElqR2JIWFBMVldWdUE?oc=5", "tier": "direct", "title": "Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss", "topics": [], "summary": "", "age_days": 7.4, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "negative", "story_key": "56fad0a1cd861616493f9fdca25798a89911c98461b81d9f27bc916bf87bc7b9", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYUt0Ri16b2dUaXNIUkVjUHdBeHJrTUdMVHhoUldpMkZFbjlZQUdNQ0lXaU1FV3MxZUcyYjdxR2ZSQ0k2OEMyd2ZUNDhMRHlzWTJIYURSa19OLXRLNTRPMGd2THQ1cFd3YkRoMVR3czNNaXd2YVZtbTlhdzZsbnowcWtHdHJIQUZUaXlyLUtYeFZKRzBueGdsdVhNNTYzMElqR2JIWFBMVldWdUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T12:45:37+00:00", "source_names": ["Stock Titan"], "target_scope": "Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 48.0, "sentiment_pct": 42, "evidence_basis": "headline_only", "evidence_share": 14.9, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.066069, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.465, "provider_symbols": ["IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 44, "published_display": "28 Aug 2026 12:45", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.9", "target_provider_symbol": "IMRN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://seekingalpha.com/news/4637804-immuron-reports-fy-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "tier": "direct", "title": "Immuron reports FY results", "topics": ["Earnings", "Earnings News", "Ratings"], "summary": "* Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. * Net loss of A$3.8M, improvement of A$1.4M. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking Alpha\u2019s Quant Rating on Immuron [https://seekingalpha.com/symbol/IMRN/ratings/quant-ratings] * Historical earnings data for ", "age_days": 7.5, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "d8e226d34cf6268c47d48dcb1beeb4b0bca74c23d0fa6175fb3828adfc70bbbf", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4637804-immuron-reports-fy-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-28T10:12:40+00:00", "source_names": ["seekingalpha.com"], "target_scope": "Immuron reports FY results * Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking Alpha\u2019s Quant Rating on Immuron [https://seekingalpha.com/symbol/IMRN/ratings/quant-ratings] * Historical earnings data for", "tone_signals": ["Operating growth"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.043278, "influence_label": "None", "provider_symbol": "IMRN.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.512, "provider_symbols": ["IMRN.ARCHIVE", "IMRN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:12", "direction_included": false, "sentiment_conflict": 0.195, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN.US", "provider_directional_mass": 0.1952}, {"url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQjNqX2xpbmdDTGhuUUdvbFNTT2YwUkQxczBEaThnblJvbXNQYlFrempwRWpNT2U1amhmamhTaUZuNHdOLWdTOFNsSms4R0QzUldZaVJFckIxa1dNc010U015dDMtS3Bua1JqVXJJMXMwelJXMDVhQTlJYU1yeV85VXRvZVZrSHZUSElCTjBZWG9uS0ZlOHBCUENNVG00Q1VWUEttbnVORDBPbkh6NklsdFdZbWl5ajFRb09UMUhR?oc=5", "tier": "direct", "title": "Immuron Limited Reports Record FY26 Sales, Improved Profit and Key Pipeline Milestones", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "98767e5c8220798dcf507e0c34f9cf3f5157bf46a7ff618d24fb5239e53559e4", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQjNqX2xpbmdDTGhuUUdvbFNTT2YwUkQxczBEaThnblJvbXNQYlFrempwRWpNT2U1amhmamhTaUZuNHdOLWdTOFNsSms4R0QzUldZaVJFckIxa1dNc010U015dDMtS3Bua1JqVXJJMXMwelJXMDVhQTlJYU1yeV85VXRvZVZrSHZUSElCTjBZWG9uS0ZlOHBCUENNVG00Q1VWUEttbnVORDBPbkh6NklsdFdZbWl5ajFRb09UMUhR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-08-28T10:11:00+00:00", "source_names": ["Quiver Quantitative"], "target_scope": "Immuron Limited Reports Record FY26 Sales, Improved Profit and Key Pipeline Milestones", "tone_signals": ["Operating growth"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.2, "sentiment_pct": 71, "evidence_basis": "headline_only", "evidence_share": 15.7, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.06968, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.59, "provider_symbols": ["IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 55, "published_display": "28 Aug 2026 10:11", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "15.7", "target_provider_symbol": "IMRN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWlp3N1M4NjFrUHBzTnVyRWFackk3a25QZjJBUnZ3cjh0NE91S2syZ1FPVzYtbFNMWTlZTlBWS3djSE84dGlubVlqYzFpdENJQW9xd28ycjNRMmhQejUzLWFaQkJRNHdKNVFOSHV2dFowRXhQcHVlRGl6eXdHeUpEOXJ2NzBMdExDRzkxWDZTcjk?oc=5", "tier": "direct", "title": "Immuron's cash rose A$6.2M to A$9M; its C. diff drug is ready for Phase 2", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "1fe76c5bb5743a6ec144bc2ff8d9729c4b2737a2b6ee007a70698e656d85243c", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWlp3N1M4NjFrUHBzTnVyRWFackk3a25QZjJBUnZ3cjh0NE91S2syZ1FPVzYtbFNMWTlZTlBWS3djSE84dGlubVlqYzFpdENJQW9xd28ycjNRMmhQejUzLWFaQkJRNHdKNVFOSHV2dFowRXhQcHVlRGl6eXdHeUpEOXJ2NzBMdExDRzkxWDZTcjk?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T10:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Immuron's cash rose A$6.2M to A$9M", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 47.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.044859, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/immuron-reports-fy26-preliminary-results-100000596.html", "tier": "direct", "title": "Immuron Reports FY26 Preliminary Results", "topics": [], "summary": "", "age_days": 7.5, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "c7b7e6e0cb01dda3dbde943255eb647667f6864a322f78946c1e4046d0710ee3", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-reports-fy26-preliminary-results-100000596.html", "source_name": "GlobeNewswire", "published_at": "2026-08-28T10:00:00+00:00", "source_names": ["GlobeNewswire"], "target_scope": "Immuron Reports FY26 Preliminary Results", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.0328, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 10:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": null}, {"url": "https://kalkine.com.au/news/announcements/immuron-limited-reports-59-revenue-rise-and-reduced-full-year-loss-in-appendix-4e", "tier": "direct", "title": "Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan\u00ae sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.", "age_days": 7.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "d6dee6c1fb9747e028cdffd1c30b32dca6fb129892776baa83f32db0e1687443", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkine.com.au/news/announcements/immuron-limited-reports-59-revenue-rise-and-reduced-full-year-loss-in-appendix-4e", "source_name": "Kalkine", "published_at": "2026-08-28T09:15:00", "source_names": ["Kalkine"], "target_scope": "Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan\u00ae sales in Australia and North America. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.", "tone_signals": ["Loss narrowed", "Operating growth"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.0, "sentiment_pct": 81, "evidence_basis": "archived_article", "evidence_share": 28.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.127612, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.792, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 67, "published_display": "28 Aug 2026 09:15", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "28.8", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.408}, {"url": "https://kalkinemedia.com/au/news/announcements/immuron-reports-6-rise-in-fy26-global-sales-to-77-million-with-improved-net-loss", "tier": "direct", "title": "Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.", "age_days": 7.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "b863659b1ecc41d6643603166f58e2109c8bde92b9dd037f1b8be9f70688d5e5", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/au/news/announcements/immuron-reports-6-rise-in-fy26-global-sales-to-77-million-with-improved-net-loss", "source_name": "Kalkine Media", "published_at": "2026-08-28T09:15:00", "source_names": ["Kalkine Media"], "target_scope": "Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.", "tone_signals": ["Operating growth", "Improving financial comparison", "Fda Approval"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.0, "sentiment_pct": 65, "evidence_basis": "archived_article", "evidence_share": 21.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.0966, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.787, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 52, "published_display": "28 Aug 2026 09:15", "direction_included": true, "sentiment_conflict": 0.277, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "21.8", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.3227}, {"url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-b9182ccdda73.html", "tier": "direct", "title": "Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and ProIBS, while seeking partners to fund the development and commercialization of its clinical assets IMM-124E and IMM-529. This shift aims to reduce R&D expenditure and cash burn, leveraging upfront fees, milestones, and royalties from licensing agreements.", "age_days": 16.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "43e854c67794c33350f84a4d8216f6adbae2b3bc7e9f910b42194af9230a1ff7", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-b9182ccdda73.html", "source_name": "Stock Titan", "published_at": "2026-08-19T10:11:00", "source_names": ["Stock Titan"], "target_scope": "Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S.", "tone_signals": ["Cash generation improved", "Strategic partnership"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 10.1, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 4.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.020181, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.648, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 37, "published_display": "19 Aug 2026 10:11", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.6", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.312}, {"url": "https://kalkine.com.au/news/announcements/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference", "tier": "direct", "title": "Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan\u00ae for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS\u00ae for IBS symptoms.", "age_days": 17.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "4135b69221dd3147547025a8e458443eff7676db222212187f65acfba087ad95", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkine.com.au/news/announcements/immuron-ceo-steven-lydeamore-to-present-at-emerging-growth-conference", "source_name": "Kalkine", "published_at": "2026-08-18T23:40:25", "source_names": ["Kalkine"], "target_scope": "Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan\u00ae for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS\u00ae for IBS symptoms.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.009136, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Aug 2026 23:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.2914}, {"url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-2bd486add72e.html", "tier": "direct", "title": "Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference", "topics": ["Earnings", "Life Sciences"], "summary": "Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelan\u00ae for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, and the distribution of ProIBS\u00ae for IBS symptoms. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.", "age_days": 22.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "23c5df8b243cca91e87a425f3ba19d99ef0bd7962388c280c16eba4bd50f32f1", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-2bd486add72e.html", "source_name": "Stock Titan", "published_at": "2026-08-13T09:42:33", "source_names": ["Stock Titan"], "target_scope": "Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.004214, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 09:42", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.2789}, {"url": "https://kalkinemedia.com/au/news/announcements/immuron-ceo-steven-lydeamore-to-deliver-virtual-presentation-at-emerging-growth-conference-on-august-19-2026", "tier": "direct", "title": "Immuron CEO Steven Lydeamore to Deliver Virtual Presentation at Emerging Growth Conference on August 19, 2026", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Eastern Time. The company, an Australian biopharmaceutical firm, specializes in orally delivered targeted polyclonal antibodies for infectious diseases, with its flagship product Travelan AE targeting travelers' diarrhea. Immuron is also developing IMM-529 for Clostridioides difficile infection.", "age_days": 22.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "7d43537d81ddb98496de7cb014cea406cc6ac1a7ee1db4480a30132fa9bf7829", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/au/news/announcements/immuron-ceo-steven-lydeamore-to-deliver-virtual-presentation-at-emerging-growth-conference-on-august-19-2026", "source_name": "Kalkine Media", "published_at": "2026-08-13T09:15:00", "source_names": ["Kalkine Media"], "target_scope": "Immuron CEO Steven Lydeamore to Deliver Virtual Presentation at Emerging Growth Conference on August 19, 2026 Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Immuron is also developing IMM-529 for Clostridioides difficile infection.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.004203, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["IMRN", "IMRN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 09:15", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "IMRN", "provider_directional_mass": 0.3413}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 55, "display": "55", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 30, "display": "30", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "15 company stories"}, {"label": "Story agreement", "value": 87, "display": "87", "tone": "positive", "note": "13/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 9, "note": "0.443 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "5 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 35, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 87, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 79, "note": "less reliance on one publisher"}], "freshness": 35, "source_independence": 79, "timeline": [{"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-15", "label": "15 Aug", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-17", "label": "17 Aug", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-18", "label": "18 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-19", "label": "19 Aug", "count": 1, "score": 59, "tone": "positive", "x": 389.4, "y": 118.6, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-20", "label": "20 Aug", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-21", "label": "21 Aug", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-22", "label": "22 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-23", "label": "23 Aug", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-24", "label": "24 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-25", "label": "25 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-26", "label": "26 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-27", "label": "27 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-28", "label": "28 Aug", "count": 7, "score": 63, "tone": "positive", "x": 673.7, "y": 111.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-01", "label": "01 Sep", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-02", "label": "02 Sep", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-04", "label": "04 Sep", "count": 4, "score": 52, "tone": "neutral", "x": 894.8, "y": 131.4, "volume_height": 29.7, "volume_y": 236.3}, {"date": "2026-09-05", "label": "05 Sep", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-06", "label": "06 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "199.9,135.0 357.9,135.0 389.4,118.6 673.7,111.3 894.8,131.4", "timeline_has_signal": true, "timeline_start": "08 Aug", "timeline_mid": "23 Aug", "timeline_end": "06 Sep", "momentum": {"label": "Establishing", "tone": "neutral", "recent_score": 52, "prior_score": null, "delta": null, "recent_count": 4, "prior_count": 0, "volume_delta": 4, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 52, "delta": null, "latest_count": 0, "baseline_count": 4, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 4, "share": 27}, {"label": "4 to 7 days", "count": 0, "share": 0}, {"label": "8 to 14 days", "count": 7, "share": 47}, {"label": "15 to 21 days", "count": 2, "share": 13}, {"label": "22 to 30 days", "count": 2, "share": 13}], "source_profile": [{"label": "Stock Titan", "count": 4, "share": 27, "score": 47, "tone": "neutral"}, {"label": "Kalkine", "count": 2, "share": 13, "score": 79, "tone": "positive"}, {"label": "Kalkine Media", "count": 2, "share": 13, "score": 64, "tone": "positive"}, {"label": "GlobeNewswire", "count": 2, "share": 13, "score": 50, "tone": "neutral"}, {"label": "Quiver Quantitative", "count": 1, "share": 7, "score": 71, "tone": "positive"}, {"label": "Stocktwits", "count": 1, "share": 7, "score": 57, "tone": "neutral"}, {"label": "MT Newswires", "count": 1, "share": 7, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 9, "share": 60, "score": 67, "tone": "positive"}, {"label": "Market update", "count": 3, "share": 20, "score": 53, "tone": "neutral"}, {"label": "Balance sheet", "count": 2, "share": 13, "score": 45, "tone": "neutral"}, {"label": "Deals and strategy", "count": 1, "share": 7, "score": 50, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 7, "share": 47}, {"label": "Life Sciences", "count": 6, "share": 40}, {"label": "Finance", "count": 3, "share": 20}, {"label": "Ratings", "count": 1, "share": 7}, {"label": "Earnings News", "count": 1, "share": 7}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to IMRN."}, {"label": "Source breadth", "text": "The score uses 5 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.443."}, {"label": "Confidence", "text": "Confidence is 30/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "tier": "direct", "title": "Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/immuron-signs-exclusive-us-distribution-175127674.html", "source_name": "MT Newswires", "published_at": "2026-09-04T17:51:27+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 98.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.069227, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 17:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 15, "updated_at": "2026-09-04T22:52:32.562457+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 193.4, "label": "13 Mar 2026", "close": 0.783, "index": 100.0}, {"x": 78.4, "y": 204.2, "label": "20 Mar 2026", "close": 0.703, "index": 89.8}, {"x": 114.9, "y": 190.4, "label": "27 Mar 2026", "close": 0.80496, "index": 102.8}, {"x": 151.3, "y": 190.9, "label": "03 Apr 2026", "close": 0.801, "index": 102.3}, {"x": 187.7, "y": 192.0, "label": "10 Apr 2026", "close": 0.793, "index": 101.3}, {"x": 224.2, "y": 169.7, "label": "17 Apr 2026", "close": 0.9578, "index": 122.3}, {"x": 260.6, "y": 178.4, "label": "24 Apr 2026", "close": 0.8935, "index": 114.1}, {"x": 297.0, "y": 192.2, "label": "01 May 2026", "close": 0.792, "index": 101.1}, {"x": 333.5, "y": 190.4, "label": "08 May 2026", "close": 0.8049, "index": 102.8}, {"x": 369.9, "y": 163.3, "label": "15 May 2026", "close": 1.005, "index": 128.4}, {"x": 406.3, "y": 164.0, "label": "22 May 2026", "close": 1.0, "index": 127.7}, {"x": 442.8, "y": 103.1, "label": "29 May 2026", "close": 1.45, "index": 185.2}, {"x": 479.2, "y": 130.2, "label": "05 Jun 2026", "close": 1.25, "index": 159.6}, {"x": 515.6, "y": 138.3, "label": "12 Jun 2026", "close": 1.19, "index": 152.0}, {"x": 552.0, "y": 155.9, "label": "19 Jun 2026", "close": 1.06, "index": 135.4}, {"x": 588.5, "y": 150.5, "label": "26 Jun 2026", "close": 1.1, "index": 140.5}, {"x": 624.9, "y": 150.5, "label": "03 Jul 2026", "close": 1.1, "index": 140.5}, {"x": 661.3, "y": 132.9, "label": "10 Jul 2026", "close": 1.23, "index": 157.1}, {"x": 697.8, "y": 135.6, "label": "17 Jul 2026", "close": 1.21, "index": 154.5}, {"x": 734.2, "y": 149.1, "label": "24 Jul 2026", "close": 1.11, "index": 141.8}, {"x": 770.6, "y": 151.8, "label": "31 Jul 2026", "close": 1.09, "index": 139.2}, {"x": 807.1, "y": 159.8, "label": "07 Aug 2026", "close": 1.031, "index": 131.7}, {"x": 843.5, "y": 150.5, "label": "14 Aug 2026", "close": 1.1, "index": 140.5}, {"x": 879.9, "y": 147.8, "label": "21 Aug 2026", "close": 1.12, "index": 143.0}, {"x": 916.4, "y": 143.7, "label": "28 Aug 2026", "close": 1.15, "index": 146.9}, {"x": 952.8, "y": 55.8, "label": "04 Sep 2026", "close": 1.8, "index": 229.9}], "sentiment_points": [{"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 51, "tone": "neutral", "raw_score": 59, "confidence": 29, "stories": 1, "close": 1.06, "price_change": -10.9, "x": 557.2, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 59, "confidence": 20, "stories": 4, "close": 1.1, "price_change": 3.8, "x": 593.7, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 59, "confidence": 16, "stories": 6, "close": 1.1, "price_change": 0.0, "x": 630.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 59, "confidence": 25, "stories": 7, "close": 1.23, "price_change": 11.8, "x": 666.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 58, "tone": "positive", "raw_score": 80, "confidence": 31, "stories": 16, "close": 1.21, "price_change": -1.6, "x": 703.0, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 53, "tone": "neutral", "raw_score": 66, "confidence": 27, "stories": 18, "close": 1.11, "price_change": -8.3, "x": 739.4, "y": 124.5, "show_label": false, "label_y": 114.5}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 27, "stories": 27, "close": 1.09, "price_change": -1.8, "x": 775.8, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 53, "tone": "neutral", "raw_score": 65, "confidence": 26, "stories": 27, "close": 1.031, "price_change": -5.4, "x": 812.3, "y": 124.5, "show_label": false, "label_y": 114.5}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 51, "tone": "neutral", "raw_score": 65, "confidence": 19, "stories": 26, "close": 1.1, "price_change": 6.7, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 60, "confidence": 27, "stories": 16, "close": 1.12, "price_change": 1.8, "x": 885.1, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 58, "tone": "positive", "raw_score": 67, "confidence": 40, "stories": 12, "close": 1.15, "price_change": 2.7, "x": 921.6, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 54, "tone": "neutral", "raw_score": 65, "confidence": 28, "stories": 15, "close": 1.8, "price_change": 56.5, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}], "price_path": "42.0,193.4 78.4,204.2 114.9,190.4 151.3,190.9 187.7,192.0 224.2,169.7 260.6,178.4 297.0,192.2 333.5,190.4 369.9,163.3 406.3,164.0 442.8,103.1 479.2,130.2 515.6,138.3 552.0,155.9 588.5,150.5 624.9,150.5 661.3,132.9 697.8,135.6 734.2,149.1 770.6,151.8 807.1,159.8 843.5,150.5 879.9,147.8 916.4,143.7 952.8,55.8", "sentiment_path": "557.2,128.2 593.7,130.0 630.1,130.0 666.5,130.0 703.0,115.3 739.4,124.5 775.8,128.2 812.3,124.5 848.7,128.2 885.1,126.3 921.6,115.3 958.0,122.6", "score_version": "evidence-v10", "price_change": 129.9, "sentiment_change": 3, "recent_pairs": [{"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 54, "tone": "neutral", "raw_score": 65, "confidence": 28, "stories": 15, "close": 1.8, "price_change": 56.5, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 58, "tone": "positive", "raw_score": 67, "confidence": 40, "stories": 12, "close": 1.15, "price_change": 2.7, "x": 921.6, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 60, "confidence": 27, "stories": 16, "close": 1.12, "price_change": 1.8, "x": 885.1, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 51, "tone": "neutral", "raw_score": 65, "confidence": 19, "stories": 26, "close": 1.1, "price_change": 6.7, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 53, "tone": "neutral", "raw_score": 65, "confidence": 26, "stories": 27, "close": 1.031, "price_change": -5.4, "x": 812.3, "y": 124.5, "show_label": false, "label_y": 114.5}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 27, "stories": 27, "close": 1.09, "price_change": -1.8, "x": 775.8, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 53, "tone": "neutral", "raw_score": 66, "confidence": 27, "stories": 18, "close": 1.11, "price_change": -8.3, "x": 739.4, "y": 124.5, "show_label": false, "label_y": 114.5}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 58, "tone": "positive", "raw_score": 80, "confidence": 31, "stories": 16, "close": 1.21, "price_change": -1.6, "x": 703.0, "y": 115.3, "show_label": true, "label_y": 105.3}], "reconstructed": true, "latest_close": 1.8, "price_observations": 26, "sentiment_observations": 12, "sentiment_start_label": "19 Jun 2026", "sentiment_end_label": "04 Sep 2026", "sentiment_history_limited": false, "price_axis_high": 246.7, "price_axis_mid": 159.8, "price_axis_low": 73.0, "start_label": "13 Mar", "mid_label": "09 Jun", "end_label": "04 Sep", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"label": "19 Jun 23:59", "short_label": "19 Jun", "collected_at": "2026-06-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 18, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 8, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 9, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 8, "score_change_display": "+8", "confidence_change": 9, "article_change": 6, "tone": "positive", "height": 20, "articles": 15, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 16, "articles": 16, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 12, "articles": 18, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 10, "articles": 20, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -2, "tone": "neutral", "height": 8, "articles": 18, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 5, "tone": "neutral", "height": 8, "articles": 23, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": 5, "article_change": 4, "tone": "neutral", "height": 4, "articles": 27, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 27, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": -4, "article_change": 0, "tone": "neutral", "height": 8, "articles": 27, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": -9, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -8, "tone": "neutral", "height": 4, "articles": 20, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 13, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 6, "score_change_display": "+6", "confidence_change": 10, "article_change": -6, "tone": "positive", "height": 16, "articles": 12, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -4, "score_change_display": "-4", "confidence_change": -12, "article_change": 3, "tone": "neutral", "height": 8, "articles": 15, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "06 Sep 15:17", "short_label": "06 Sep", "collected_at": "2026-09-06T15:17:55.842008+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 8, "articles": 15, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 22, "span_label": "79 days", "first_score": 51, "latest_score": 54, "net_change": 3, "net_change_display": "+3", "direction": "Broadly stable", "high_score": 60, "low_score": 50, "latest_confidence": 25, "confidence_change": -4, "latest_articles": 15, "article_change": 14, "latest_label": "06 Sep 15:17", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "19 Jun 23:59", "short_label": "19 Jun", "collected_at": "2026-06-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 42.0, "y": 133.2}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 85.6, "y": 133.2}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 129.2, "y": 133.2}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 18, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 172.9, "y": 135.0}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 216.5, "y": 135.0}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 8, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 260.1, "y": 135.0}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 9, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 303.7, "y": 131.4}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 8, "score_change_display": "+8", "confidence_change": 9, "article_change": 6, "tone": "positive", "height": 20, "articles": 15, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 347.3, "y": 116.8}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 16, "articles": 16, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 391.0, "y": 120.4}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 12, "articles": 18, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 434.6, "y": 124.1}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 10, "articles": 20, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 478.2, "y": 125.9}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -2, "tone": "neutral", "height": 8, "articles": 18, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 521.8, "y": 127.7}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 5, "tone": "neutral", "height": 8, "articles": 23, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 565.4, "y": 127.7}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": 5, "article_change": 4, "tone": "neutral", "height": 4, "articles": 27, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 609.0, "y": 131.4}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 27, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 652.7, "y": 131.4}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": -4, "article_change": 0, "tone": "neutral", "height": 8, "articles": 27, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 696.3, "y": 127.7}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": -9, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 739.9, "y": 131.4}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -8, "tone": "neutral", "height": 4, "articles": 20, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 783.5, "y": 133.2}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 13, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 827.1, "y": 131.4}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 6, "score_change_display": "+6", "confidence_change": 10, "article_change": -6, "tone": "positive", "height": 16, "articles": 12, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 870.8, "y": 120.4}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -4, "score_change_display": "-4", "confidence_change": -12, "article_change": 3, "tone": "neutral", "height": 8, "articles": 15, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 914.4, "y": 127.7}, {"label": "06 Sep 15:17", "short_label": "06 Sep", "collected_at": "2026-09-06T15:17:55.842008+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 8, "articles": 15, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 958.0, "y": 127.7}], "chart_points": "42.0,133.2 85.6,133.2 129.2,133.2 172.9,135.0 216.5,135.0 260.1,135.0 303.7,131.4 347.3,116.8 391.0,120.4 434.6,124.1 478.2,125.9 521.8,127.7 565.4,127.7 609.0,131.4 652.7,131.4 696.3,127.7 739.9,131.4 783.5,133.2 827.1,131.4 870.8,120.4 914.4,127.7 958.0,127.7", "changes": [{"label": "06 Sep 15:17", "short_label": "06 Sep", "collected_at": "2026-09-06T15:17:55.842008+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 8, "articles": 15, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -4, "score_change_display": "-4", "confidence_change": -12, "article_change": 3, "tone": "neutral", "height": 8, "articles": 15, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 6, "score_change_display": "+6", "confidence_change": 10, "article_change": -6, "tone": "positive", "height": 16, "articles": 12, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 13, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -8, "tone": "neutral", "height": 4, "articles": 20, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": -9, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": -4, "article_change": 0, "tone": "neutral", "height": 8, "articles": 27, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 27, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}